[16] Still, one must exercise caution when drawing generalized conclusions. Although the majority of studies indicate that patients are able to tolerate higher doses than HVs, there are examples where there is no difference or even the opposite is true.[2,17] Furthermore,

conflicting outcomes within the same drug class (e.g. acetylcholinesterase inhibitors)[12,17] suggest that specific molecule differences may play a contributory role. Such divergent findings underscore the importance of carefully evaluating tolerability in the target population prior to embarking on phase II see more efficacy trials of any new investigational drug. While the cumulative MTD literature in schizophrenia and Alzheimer’s disease can lend some GSK1210151A datasheet guidance to drug developers in the CNS arena, published data are comparatively GSK2118436 cost sparse for other indications, including major depressive disorder (MDD). The current paper summarizes the bridging data for Org 26576 (chemical name: [9aS]-8,9,9a,10-tetrahydro-5H,7H-pyrido[3,2-f]pyrrolo[2,1-c][1,4]oxazepin-5-one;

see figure 1). Org 26576 belongs to a novel class of compounds referred to as alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor positive allosteric modulators (AMPA PAMs), which act by modulating ionotropic AMPA-type glutamate receptors to enhance glutamatergic neurotransmission.[18,19] Dysregulation of the glutamatergic system has

been implicated in the pathology of psychiatric diseases such as schizophrenia[20,21] and mood disorders.[22–24] AMPA receptors mediate fast excitatory neurotransmission in the brain, and their activation has been reported to exert a variety of cellular effects, including enhancement of neurotrophic factor activity (particularly brain-derived neurotrophic heptaminol factor [BDNF]),[25] synaptic plasticity,[26] and neurogenesis.[27] It has been suggested that modulation of these cellular activities may, in part, play a role in the mode of action of current antidepressant agents.[28,29] If so, AMPA PAMs represent a promising novel approach in MDD. Fig. 1 Chemical structure of Org 26576. The two trials presented here were undertaken by employing very similar designs and dosing approaches in order to characterize the tolerability, safety, and pharmacokinetic profiles of Org 26576 both in HVs and in patients diagnosed with MDD. The overarching program objective of these trials was to facilitate dose selection for the first proof-of-concept trials with Org 26576 in MDD. HV and patient safety/tolerability and pharmacokinetic data that contributed to dosing decisions are presented here. Secondary, exploratory pharmacodynamic endpoints from the patient trial are presented elsewhere.